Table 1.
Baseline Patient and Tumor Characteristics
| No Trastuzumab (n = 116) |
Trastuzumab (n = 128) |
P Value | |
|---|---|---|---|
| N (%) | N (%) | ||
| Median age, years (range) | 64 (55–87) | 62 (55–87) | .13 |
| 55–60 years | 40 (34) | 50 (39) | |
| 60–70 years | 46 (40) | 56 (44) | |
| >70 years | 30 (26) | 22 (17) | |
| Tumor size | |||
| Median, cm (range) | 1.1 (0.1–2.0) | 1.2 (0.25–2.0) | .63 |
| T1a | 29 (25) | 12 (9) | |
| T1b | 23 (20) | 34 (26) | |
| T1c | 64 (55) | 82 (64) | |
| Multifocal | 21 (18) | 19 (15) | .49 |
| Histology | |||
| Ductal | 106 (91) | 120 (94) | |
| Lobular | 5 (4) | 4 (3) | |
| Other, including mixed | 5 (4) | 4 (3) | |
| Grade | .001 | ||
| 1 | 4 (3) | 0 (0) | |
| 2 | 25 (22) | 12 (9) | |
| 3 | 77 (66) | 112 (88) | |
| Unknown | 10 (9) | 4 (3) | |
| Lymphovascular invasion | |||
| Present | 9 (8) | 30 (23) | .001 |
| Absent | 100 (86) | 93 (73) | |
| Unknown | 7 (6) | 5 (4) | |
| Estrogen receptor status | |||
| Positive | 77 (66) | 75 (59) | <.001 |
| Negative | 38 (33) | 53 (41) | |
| Unknown | 1 (1) | 0 (0) | |
| Surgery | |||
| Breast conserving | 78 (67) | 80 (63) | |
| Mastectomy | 38 (33) | 48 (38) | |
| Adjuvant radiation | 79 (68) | 77 (60) | .16 |
| Left-side radiation | 33 (28) | 37 (29) | |
| Adjuvant hormonal therapy | 77 (66) | 69 (54) | .0175 |
| Adjuvant chemotherapy | 61 (53) | 126 (98) | <.0001 |
| Anthracycline/no taxane | 46 (40) | 9 (7) | |
| Taxane/no anthracycline | 0 (0) | 64 (50) | |
| Anthracycline and taxane | 1 (1) | 43 (34) | |
| Other | 14 (12) | 10 (8) |
Grade 2–3, classified as 3.
Note: Percentages may not add to 100 due to rounding.